Navigation Links
Positive Results Using Affitech-Identified Human Antibody That,Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model,Reported by Peregrine

OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, the human antibody therapeutics company announced today that Peregrine Pharmaceuticals, Inc. reported positive in vivo test results of R3, a fully human monoclonal antibody developed by Affitech, in a pancreatic cancer model at the recently concluded Centennial Annual Meeting of the American Association for Cancer Research (AACR). R3 has been designed by the two companies for selective blocking of VEGF (vascular endothelial growth factor) binding to VEGF receptor 2, as opposed to other anti-angiogenic agents which block activity of both VEGF receptors.

The R3 antibody, which was generated by Affitech's phagemid antibody library screening method, when tested by Peregrine on a pancreatic cancer model, showed significant reduction of the growth, vascularization and macrophage infiltration of pancreatic tumors in mice. This is the first antibody from Affitech's library that has been tested in a preclinical development model. Peregrine announced that the positive results of R3 antibody support the Company's intent to progress its anti-VEGF program towards clinical trials.

"We are delighted with this in vivo result, " commented Martin Welschof, Ph.D., Chief Executive Officer of Affitech. "Affitech and Peregrine have several collaborative antibody projects. The quality of the antibody and excellent collaborative research by the scientists of our two organizations are contributing to advancing Peregrine's anti-VEGF portfolio. This success also has important implications for accelerating our own human therapeutic antibody program "

Editors notes

Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company's current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies - (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN(TM) technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery is based on CBAS(TM) technology, which is a "reverse-screening" approach for discovering antibodies and their cognate targets utilizing disease-specific cells. Several of the Company's proprietary product candidates currently in development were generated by CBAS(TM). Affitech also sells its proprietary Protein L product line for the purification of antibody and antibody fragments. Affitech offers collaborators a flexible business model and very competitive price structure with low royalty stacking. The Company has concluded deals with commercial organizations such as Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, Pharmexa and others. Further information at


Affitech (Norway)
Dr. Martin Welschof
Chief Executive Officer
+47 22 95 87 58
Affitech (USA)
Dr. Rathin C. Das
+ 1 925 935 9803
Media enquiries
Hayhurst Media
Richard Hayhurst
+44 7711 821527


Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the German ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... Dental Association meeting in Washington D.C. revolved around the fact that proper dental care, ... The talk stressed the link between periodontal disease (more commonly referred to as gum ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... care in America. As people age, more care is needed, especially with Alzheimer’s, ... and medical professionals are being overworked. The forgotten part of this equation: 80 ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ProSidebar: ... in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily add ... ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group ... group of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec ...
Breaking Medicine News(10 mins):